CELU celularity.com: Forward P/S Multiple
Celularity Inc. management is currently adapting its cellular platform for full-scale commercialization and monetization of biomaterials. Production stability is ensured by proprietary plants and cryostorage facilities in New Jersey featuring strict sterile control. Placenta-based tissue regeneration technology creates potential for pricing power. The forward P/S trend reflects market expectations, where 1.10 represents the latest metric reading.
Metric breakdowns and analytics for celularity.com (CELU)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
- financial results and valuation multiples details:
CELU - Net Financial Result|Future Profit Celularity Inc.|CELU - Market Price to Net Income Ratio|Projected Price to Earnings Celularity|CELU - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Celularity Inc.|CELU - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Celularity|CELU - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months celularity.com|CELU - Earnings per share growth this year|Earnings growth forecast for next year Celularity Inc.
- revenue and sales details:
Summary company analytics:Celularity Corp CELU
The business resilience of Celularity Inc. (CELU) depends on the commercialization of placental therapy and the sale of biomaterials for regenerative medicine. The projected P/S dynamics correlate the company's current market value with expected revenue, accounting for the impact of interest rates on the cost of capital. An increase in this ratio signals inflated market expectations, which raises the risk of a price correction toward a fair value level.
Competitors of Celularity Inc.
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|ADMA Corp (ADMA) - Forward Price-to-Revenue Multiple|PTGX: Forward P/S Multiple|Market Cap to Future Revenue Ratio immunovant.com (IMVT)|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|biocryst.com - Price-to-Projected Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|DNTH - Forward P/S Multiple|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|AbCellera Corp - Forward Price to Sales|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple PHAR (Pharming Group)|Price to Expected Revenue Ratio NKTR|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Zenas Corp (ZBIO) - Market Cap to Future Revenue Ratio|IMNM: Forward Price-to-Revenue Multiple|Forward Price to Sales GOSS (gossamerbio.com)|KALV: Forward P/S Multiple|SEPN - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals Inc|Market Cap to Projected Revenue SVRA (Savara Pharma)|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio enGene Holdings Inc (ENGN)|RAPT Therapeutics, Inc. - Forward P/S Multiple|Aerovate Therapeutics Inc (JBIO) - Forward Price-to-Revenue Multiple|ACRS: Forward P/S Multiple|Market Cap to Future Revenue Ratio kyvernatx.com (KYTX)|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|Price-to-Projected Revenue Ratio CABA|Forward Price-to-Revenue Multiple VTYX (Ventyx Bio)|Forward P/S Multiple Theratechnologies, Inc (THTX)|Price-to-Projected Revenue Ratio Avalo Therapeutics, Inc AVTX|ELDN (eledon.com) - Future Price to Revenue|Agenus Inc. - Forward P/S Multiple|Forward Price to Sales CLYM (Climb Bio Inc.)|ZURA: Forward P/S Multiple|aTyr Pharmaceuticals (ATYR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Adagene Inc|IMA: Forward Price to Sales|Price-to-Projected Revenue Ratio Shattuck Labs, Inc. (STTK)|Forward Price-to-Revenue Multiple equilliumbio.com EQ|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA: Forward Price-to-Revenue Multiple|Forward Price to Sales IFRX (InflaRx N.V.)|XFOR: Forward P/S Multiple|ACET - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio INmune Bio Corp|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|Forward Price-to-Revenue Multiple sabbiotherapeutics.com SABS|Akari Therapeutics Plc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Enlivex Therapeutics Ltd ENLV|QTTB - Price-to-Projected Revenue Ratio|GOVX (GeoVax Corp) - Market Cap to Projected Revenue|EDSA: Forward P/S Multiple|Market Cap to Future Revenue Ratio ibioinc.com (IBIO)|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple XTL Biopharmaceuticals Ltd (XTLB)|Forward P/S Multiple BOLT|HCWB - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM ImmunoTech, Inc. - Price-to-Projected Revenue Ratio|ADTX: Forward Price-to-Revenue Multiple|GRI - Forward P/S Multiple|XORTX (XRTX) - Price-to-Projected Revenue Ratio|HIND (Vyome Therapeutics) - Price-to-Projected Revenue Ratio|REVB (Revelation Biosciences) - Forward P/S Multiple|Forward P/S Multiple indaptusrx.com|Price-to-Projected Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Market Cap to Expected Sales Ratio Allakos Inc (ALLK)|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|ITOS (iTeos Therapeutics, Inc.) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Ocean Biomedical Inc (OCEA)|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
